Evolus, Inc. - Common Stock (EOLS)
13.41
-0.16 (-1.18%)
Evolus Inc is a beauty-focused company that specializes in aesthetic treatment products, with a particular emphasis on non-surgical cosmetic procedures
The company is renowned for its innovative solutions designed to enhance natural beauty, catering primarily to the needs of individuals seeking to improve their appearance through injectable treatments. Evolus aims to empower consumers with access to high-quality aesthetic products and services, fostering a positive self-image and confidence. The company's flagship offerings are aimed at the aesthetic physician market, supporting professionals in delivering effective and satisfying results for their clients.
![](https://www.investors.com/wp-content/uploads/2025/01/Stock-FacialWork-adobe.jpg)
The company expects to soon expand from a single-product player to a "multi-product innovator."
Via Investor's Business Daily · January 21, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/21/wall-street-chart-shutter2.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 21, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/21/Top-3-Charles-Schwab-Index-Funds-To-Boos.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 21, 2025
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · July 31, 2024
![](https://www.investors.com/wp-content/uploads/2024/07/Stock-skinfillerneedle-01-shutt.jpg)
The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss.
Via Investor's Business Daily · July 31, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
EOLS stock results show that Evolus beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street.jpg)
Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday!
Via InvestorPlace · May 2, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 21, 2024
![](https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg)
A Relative Strength Rating upgrade for AbbVie shows improving technical performance.
Via Investor's Business Daily · February 14, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 7, 2024
![](https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg)
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level.
Via Investor's Business Daily · February 1, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/29/image21.jpeg?width=1200&height=800&fit=crop)
Shares of Panbela Therapeutics, Inc. (NASDAQPBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped 65.5% to $1.47 on Monday.
Via Benzinga · January 29, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/29/image46.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQSOFI) rose sharply during Monday’s session after the company reported better-than-expected fourth-quarter revenue.
Via Benzinga · January 29, 2024
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • CI&T (NYSECINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via Benzinga · March 7, 2024
![](https://cdn.benzinga.com/files/images/story/2024/evolus-shutter.jpeg?width=1200&height=800&fit=crop)
Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Evolus.
Via Benzinga · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/AbbVie-Office.png?width=1200&height=800&fit=crop)
AbbVie Inc's (NYSEABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing potential risks, AbbVie emphasizes its commitment to safety with existing 'black box' warnings. Amidst economic uncertainties and emerging competitors, AbbVie anticipates continued strength.
Via Benzinga · January 11, 2024
![](https://cdn.benzinga.com/files/images/story/2023/12/12/botox-photo_by_anva_marketing_via_pexels.jpg?width=1200&height=800&fit=crop)
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to Botox and similar injections.
Via Benzinga · December 12, 2023